Giant Biogene (02367) announced its financial results for 2025. Revenue reached approximately RMB 5.5185 billion, representing a decrease of 0.4% year-on-year. Gross profit was approximately RMB 4.4334 billion, down 2.5% compared to the previous year. Profit attributable to owners of the parent company was approximately RMB 1.915 billion, a reduction of 7.2% year-on-year. Adjusted net profit was approximately RMB 1.96 billion, declining by 8.9% compared to the prior year. Basic earnings per share were RMB 1.83. The company proposed a final dividend of RMB 0.5390 per share and a special dividend of RMB 0.6714 per share.
The announcement stated that overall revenue remained largely stable, primarily influenced by changes in sales of professional skin care products. Revenue from functional skincare products increased due to the company's ongoing enhancement of omni-channel marketing activities, sustained volume growth of the star product, Refixar Focus Cream, and the successful launch of the upgraded version 3.0 of Colorkey Big Film King. Revenue from medical dressings saw a decline, mainly attributed to the company's proactive strengthening of sales channel controls to maintain product pricing systems, which had a temporary impact on short-term revenue scale. The decrease in gross profit was primarily due to the reduction in sales revenue and an increase in cost of sales.
Comments